Scribe Therapeutics (SCTX) Director Carl L. Gordon Buys 1,000,000 Shares

What Happened
Carl L. Gordon, a director of Scribe Therapeutics (SCTX), reported a $15.0 million purchase of 1,000,000 shares at $15.00 per share in the issuer's offering (IPO). The Form 4 also reports the automatic conversion of Series B preferred stock into common stock upon the IPO closing: 348,825 common shares were recorded as acquired through conversion, and 2,065,672 derivative-share units were reported as disposed at $0 (reflecting the conversion of the derivative preferred stock, not a cash sale).

Key Details

• Transaction date(s): July 27, 2026; Form filed July 29, 2026. Filing appears timely (no late filing indicated).
• Open-market/private purchase: 1,000,000 shares @ $15.00 = $15,000,000 (Footnote F2: purchased in the IPO).
• Conversions (derivative activity): +348,825 common shares acquired by automatic conversion of Series B Preferred; 2,065,672 derivative-share units reported disposed at $0 (Footnote F1: conversion occurred on IPO close on 7/27/2026 on a 1-for-0.1689 basis).
• Shares owned after the transaction: not specified in the information provided in this summary filing.
• Ownership/filing notes: Some reported interests are held by OrbiMed Private Investments VIII, LP and related OrbiMed entities; OrbiMed entities and the reporting person include disclaimers of beneficial ownership except to the extent of any pecuniary interest (Footnotes F3–F4).

Context
The $15M purchase is a direct cash purchase in the IPO and is typically more informative than routine sales because it increases insider exposure. The “disposed at $0” derivative entries reflect conversion of preferred stock into common shares at IPO closing (per Footnote F1) rather than a market sale. The filing shows both an institutional/affiliate structure (OrbiMed-related holdings) and the director-level transaction; no conclusions about motive should be drawn from the filing itself.